Vitura Health grew FY2026 revenue 6% to $131.2 million, but a sharp margin squeeze pushed the ASX-listed digital health company into a $4.4 million statutory loss. With ANZ debt classified as current and a potential $6 million FY2027 revenue hit from changed Bupa referrals, the promised turnaround faces a demanding test.
- Revenue increased 6% to $131.2 million
- Statutory loss of $4.4 million versus FY2025 profit of $3.1 million
- Gross margin fell to 19% as medicinal cannabis prices compressed
- $14.2 million of ANZ borrowings classified as current after a covenant breach
- Bupa referral changes expected to reduce FY2027 revenue by approximately $6 million
Vitura Health Limited (ASX:VIT) ended FY2026 with more customers, more Canview units and more revenue, but less financial breathing room. Revenue rose 6% to $131.2 million while the company swung from a $3.1 million profit to a $4.4 million statutory loss, generated almost no operating cash and had $14.2 million of ANZ borrowings classified as current after a debt covenant breach.
Revenue growth collides with margin compression
The central problem was not demand alone. Product sale and distribution revenue increased 4% to $100.4 million, while medical consultation and service fees rose 11% to $30.8 million. But the average selling price of products on Canview fell from $105 to $97, driving the group’s product gross margin down to 19%, about five percentage points below the prior year.
Canview still delivered operational growth: units sold increased 17% to 1.13 million, despite Vitura saying the broader Australian medicinal cannabis market declined by almost 30%. Therapeutic nicotine vaping product revenue more than doubled, and Doctors on Demand recorded 13% revenue growth with consultation volumes up 11%. Yet the extra activity did not offset pricing pressure, higher operating costs and a $1.63 million impairment charge against goodwill associated with Doctors on Demand and Cannadoc.
Justin James inherits a balance-sheet problem
The report casts new CEO Justin James as the architect of a more disciplined operating model, following the leadership transition covered in the Justin James CEO appointment. Vitura says the restructure has streamlined leadership, reduced costs and shifted the priority from absolute revenue growth towards earnings quality and a return to profitability.
That objective now has a narrower margin for error. Cash fell 29% to $5.35 million, net operating cash flow was negative $91,025 and total liabilities rose 21% to $33.8 million. Vitura breached an ANZ covenant requiring EBITDA to be at least three times bank interest expense; because a suitable waiver had not been received at 30 June, the company classified all bank debt as current. The report says the ANZ facility remains available, but only $1.62 million of its $9 million trade finance limit was undrawn at year-end.
FY2027 starts with both a cost tailwind and revenue risk
Vitura expects lower-margin activity to be rationalised in FY2027, with revenue growth moderating as management pursues a corresponding improvement in EBITDA. Early FY2027 figures have since pointed to lower operating costs and higher unaudited EBITDA, in the early FY2027 EBITDA improvement, although that update also cautioned that Bupa-related telehealth volumes still need to unwind.
The annual report puts a number on that exposure: international-member telehealth referrals from Bupa Australia are being redirected from Doctors on Demand to Hola Health, and Vitura expects the change to reduce FY2027 revenue by approximately $6 million. The company is therefore attempting to prove that cost savings and better margins can outweigh a material loss of volume, while continuing to fund its Canview platform and clinic businesses.
Legal proceedings add another unresolved thread
Vitura also disclosed ongoing Federal Circuit and Family Court proceedings brought by former CEO Geoff Cockerill over the termination of his employment. The filing records Cockerill’s allegations under the Fair Work Act and Vitura’s position that the termination was lawful and appropriate, with no outcome disclosed. A separate TGA-related matter concerns historical alleged advertising breaches involving dormant subsidiary CDA Clinics Qld, which is in liquidation and is not the entity operating Vitura’s current CDA Clinics business.
The board says FY2027 is intended to bring a return to profitability and positive operating cash flow, and the accounts have been prepared on a going-concern basis. But that expectation depends on execution, continued bank support and, if required, access to equity markets. The next meaningful evidence will be whether the new operating model can rebuild cash generation before the current debt classification and Bupa revenue loss become harder constraints.
Bottom Line?
Vitura’s turnaround case now depends on converting cost reductions and Canview volume into cash and margin before debt pressure and the Bupa referral loss narrow its options further.
Questions in the middle?
- Can Vitura restore positive operating cash flow while $14.2 million of ANZ borrowings remain classified as current?
- Will the improved margin profile offset the approximately $6 million FY2027 revenue reduction from changed Bupa referrals?
- What level of Canview pricing, clinic growth and cost savings is needed for the company to return to statutory profitability rather than only normalised EBITDA growth?